We are live on
!
Find out more
EPIM
Evelyn Partners Investment Management Portfolio holdings
AUM
$3.68B
1-Year Est. Return
21.15%
This Fund
S&P 500
This Quarter
Est. Return
+2.9%
1 Year Est. Return
+21.15%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.08B
AUM Growth
–
Cap. Flow
+$3.1B
Cap. Flow
% of AUM
100.67%
Top 10 Holdings %
Top 10 Hldgs %
47.77%
Holding
416
New
416
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$255M |
| 2 |
Amazon
AMZN
|
+$231M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$204M |
| 4 |
CRH
CRH
|
+$115M |
| 5 |
Visa
V
|
+$114M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.83% |
| 2 | Financials | 19.56% |
| 3 | Consumer Discretionary | 15.26% |
| 4 | Healthcare | 13.88% |
| 5 | Communication Services | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Warner Bros
WBD
$69.3B
| $5.47K | ﹤0.01% |
+518
| New | +$4.81K |
|
377
Adient
ADNT
$1.44B
| $5.39K | ﹤0.01% |
+313
| New | +$6.25K |
|
378
SSR Mining
SSRM
$6.63B
| $5.22K | ﹤0.01% |
+750
| New | +$4.67K |
|
|
APLS
379
DELISTED
Apellis Pharmaceuticals
APLS
| $4.79K | ﹤0.01% |
+150
| New | +$4.51K |
|
380
Albemarle
ALB
$15.1B
| $4.56K | ﹤0.01% |
+53
| New | +$5.28K |
|
381
Chemours
CC
$2.29B
| $4.29K | ﹤0.01% |
+254
| New | +$4.94K |
|
382
Solventum
SOLV
$14.5B
| $4.16K | ﹤0.01% |
+63
| New | +$4.41K |
|
383
Fortune Brands Innovations
FBIN
$5.83B
| $4.1K | ﹤0.01% |
+60
| New | +$4.81K |
|
|
MAG
384
DELISTED
MAG Silver
MAG
| $4.07K | ﹤0.01% |
+300
| New | +$4.66K |
|
385
Arcutis Biotherapeutics
ARQT
$3.3B
| $3.76K | ﹤0.01% |
+270
| New | +$2.96K |
|
386
Mattel
MAT
$4.19B
| $3.55K | ﹤0.01% |
+200
| New | +$3.78K |
|
387
Prothena Corp
PRTA
$475M
| $2.76K | ﹤0.01% |
+199
| New | +$3.14K |
|
|
KLG
388
DELISTED
WK Kellogg Co
KLG
| $2.56K | ﹤0.01% |
+142
| New | +$2.6K |
|
389
Editas Medicine
EDIT
$436M
| $2.48K | ﹤0.01% |
+1,950
| New | +$4.97K |
|
390
Embecta
EMBC
$269M
| $2.35K | ﹤0.01% |
+114
| New | +$1.87K |
|
391
Ubiquiti
UI
$35B
| $2.32K | ﹤0.01% |
+7
| New | +$2.11K |
|
392
Takeda Pharmaceutical
TAK
$55.6B
| $2.21K | ﹤0.01% |
+167
| New | +$2.29K |
|
393
Jazz Pharmaceuticals
JAZZ
$16.2B
| $1.85K | ﹤0.01% |
+15
| New | +$1.77K |
|
|
GRAL
394
GRAIL Inc
GRAL
$3.08B
| $1.68K | ﹤0.01% |
+94
| New | +$1.53K |
|
395
Nokia
NOK
$57.6B
| $1.63K | ﹤0.01% |
+368
| New | +$1.64K |
|
396
CEVA Inc
CEVA
$857M
| $1.17K | ﹤0.01% |
+37
| New | +$1.03K |
|
397
Vanguard S&P 500 ETF
VOO
$1.03T
| $1.08K | ﹤0.01% |
+2
| New | +$1.08K |
|
398
VanEck Morningstar Wide Moat ETF
MOAT
$12.3B
| $927 | ﹤0.01% |
+10
| New | +$963 |
|
|
LAC
399
Lithium Americas
LAC
$1.18B
| $891 | ﹤0.01% |
+300
| New | +$1.04K |
|
400
MasterBrand
MBC
$1.87B
| $877 | ﹤0.01% |
+60
| New | +$1.02K |
|
Similar funds
TGA
SLG
BB
CI
GCM
OCM
SPPAM
OIMU
Evelyn Partners Investment Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Evelyn Partners Investment Management, which disclosed 416 positions worth $3.08B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is Microsoft: 598,858 shares worth $252M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, followed by Financials and Consumer Discretionary.
- Evelyn Partners Investment Management's largest Q4 2024 buy was Microsoft: 598,858 shares worth $252M.
- Evelyn Partners Investment Management's ten largest holdings make up 48% of its $3.08B portfolio in Q4 2024.
- Evelyn Partners Investment Management disclosed 416 positions in Q4 2024, its first 13F filing on record.
Based on Evelyn Partners Investment Management's 13F filing for Q4 2024, filed 11 Dec 2025.